

# Scaling Up African Vaccine Manufacturing Capacity

Executive summary (I/II)



There is a **compelling need** for expanding vaccine-manufacturing capacity and capabilities across the African continent - the target defined by the PAVM is a **strong rallying cry** to initiate change



The African vaccine-manufacturing industry today is still in its very early stages but is **not starting from zero**, with a dozen African players spread across the continent



The PAVM FFA has put forward **one vision of the African vaccine-manufacturing ecosystem** based on its analysis and 2040 goals



**Many promising announcements** have been made and initiatives have been launched in the past 18 months



Manufacturers stress that **economic viability still needs to be demonstrated**, and is crucial to the success of this strategy. A few success factors should be considered, such as:

- **Large-scale facilities** need to be prioritised
- Manufacturers should be able to export their products to the **continental market**
- A mechanism will be needed to **subsidise locally manufactured vaccines**



African manufacturers identify **three major risks** to the desired economic viability:

- **Sustainability risk:** lack of concrete measures, uncoordinated effort
- **Strategic risk:** broad strategy, need for further prioritisation to guide manufacturers' efforts and investments in the short- and mid-term
- **Support risk:** concern about loss of attention and effort over time as the Covid-19 pandemic recedes

# Scaling Up African Vaccine Manufacturing Capacity

Executive summary (II/II)



There are **several prerequisites** to creating conditions for a sustainable ecosystem for African vaccine manufacturers:

- **Advance purchase agreements** from African governments
- A **review of the procurement mechanisms**
- **Financial mechanisms** to counterbalance the lack of price-competitiveness
- **Coordination mechanisms** to improve information sharing



African manufacturers should focus on **strategic and realistic priorities** to initiate change. They need to prioritise supply-constrained products with less complex end-to-end manufacturing processes in the short- and mid-term



**Donors must provide manufacturers with sufficient and sustained support.** Access to finance, Talent and Technology transfers emerged as their most pressing challenges beyond the market-access prerequisites - selection of potential initiatives identified by manufacturers:

- (1) **Access to finance:** Offer tailored and low-cost funding with longer payback periods for manufacturing facility investment projects
- (2) **Talent:** Support manufacturers to gain practical experience by funding secondments with experienced manufacturers and by bringing global experts on local sites
- (3) **Technology transfers:** Collaborate with African manufacturers and partners on technology transfer to support capacity building, before they can attract potential private partnerships.



There is an **imperative for global health stakeholders** to recognise the economic and operational reality of the African manufacturers, who have such a crucial role in attaining the public-health objectives. The **mood among stakeholders is one of optimism** - that the current and forthcoming efforts will succeed in scaling up Africa's vaccine-manufacturing capacity.